CSIMarket
 


Autolus Therapeutics Plc  (AUTL)
Other Ticker:  
 

Autolus Therapeutics Plc's Quick Ratio

AUTL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 8 below Autolus Therapeutics Plc's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 49 other companies have achieved higher Quick Ratio than Autolus Therapeutics Plc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 248 to 398.

Explain Quick Ratio?
How much Cash & cash equivalents AUTL´s has?
What are AUTL´s Current Liabilities?


AUTL Quick Ratio (Sep 30 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
Y / Y Current Liabilities Change -22.45 % 71.5 % 71.5 % 71.5 % 71.5 %
Y / Y Cash & cash equivalent Change -32.95 % 23.23 % 23.23 % 23.23 % 23.23 %
Quick Ratio MRQ 8 9.25 9.25 9.25 9.25
AUTL's Total Ranking # 398 # 248 # 387 # #
Seq. Current Liabilities Change -22.45 % 0 % 0 % 0 % 71.5 %
Seq. Cash & cash equivalent Change -32.95 % 0 % 0 % 0 % 23.23 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 50
Healthcare Sector # 220
Overall Market # 398


Quick Ratio Statistics
High Average Low
12.88 9 5.1
(Dec 31 2021)   (Dec 31 2020)




Financial Statements
Autolus Therapeutics Plc's Current Liabilities $ 32 Millions Visit AUTL's Balance sheet
Autolus Therapeutics Plc's Cash & cash equivalent $ 256 Millions Visit AUTL's Balance sheet
Source of AUTL's Sales Visit AUTL's Sales by Geography


Cumulative Autolus Therapeutics Plc's Quick Ratio

AUTL's Quick Ratio for the trailling 12 Months

AUTL Quick Ratio

(Sep 30 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
Y / Y Current Liabilities TTM Growth -22.45 % 71.5 % 71.5 % 71.5 % 71.5 %
Y / Y Cash & cash equivalent TTM Growth -32.95 % 23.23 % 23.23 % 23.23 % 23.23 %
Quick Ratio TTM 9 9.25 9.84 10.59 11.56
Total Ranking TTM # 281 # # # 414 # 430
Seq. Current Liabilities TTM Growth -22.45 % 0 % 0 % 0 % 71.5 %
Seq. Cash & cash equivalent TTM Growth -32.95 % 0 % 0 % 0 % 23.23 %


On the trailing twelve months basis In spite of the year on year decrease in AUTL's Current Liabilities to $32.05 millions, cumulative Quick Ratio to 9 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 163 other companies have achieved higher Quick Ratio than Autolus Therapeutics Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the forth quarter 2022 from 347 to 2376.

Explain Quick Ratio?
How much Cash & cash equivalents AUTL´s has?
What are AUTL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 164
Healthcare Sector # 972
Within the Market # 398


trailing twelve months Quick Ratio Statistics
High Average Low
10.87 7.74 3.12
(Dec 31 2021)   0




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Intensity Therapeutics Inc   21.61 $ 15.649  Millions$ 0.724  Millions
Cullinan Oncology Inc   21.30 $ 466.430  Millions$ 21.897  Millions
Krystal Biotech Inc   20.38 $ 562.069  Millions$ 27.583  Millions
Prokidney Corp  19.51 $ 396.334  Millions$ 20.311  Millions
Graphite Bio Inc   18.66 $ 233.986  Millions$ 12.537  Millions
Tourmaline Bio Inc   18.14 $ 147.024  Millions$ 8.105  Millions
Compass Therapeutics Inc   17.94 $ 163.703  Millions$ 9.124  Millions
Avrobio Inc   17.90 $ 105.842  Millions$ 5.912  Millions
4d Molecular Therapeutics Inc   17.60 $ 319.664  Millions$ 18.163  Millions
Icosavax Inc   17.59 $ 229.206  Millions$ 13.030  Millions
Neumora Therapeutics Inc   17.50 $ 509.565  Millions$ 29.123  Millions
Hillevax Inc   17.11 $ 324.410  Millions$ 18.958  Millions
Fusion Pharmaceuticals Inc   16.92 $ 191.348  Millions$ 11.312  Millions
Crispr Therapeutics Ag  15.64 $ 1,739.826  Millions$ 111.234  Millions
Denali Therapeutics Inc   15.58 $ 1,109.256  Millions$ 71.180  Millions
Cabaletta Bio Inc   15.49 $ 164.391  Millions$ 10.616  Millions
Voyager Therapeutics Inc   14.51 $ 252.936  Millions$ 17.427  Millions
Pharmacyte Biotech Inc   14.01 $ 73.425  Millions$ 5.240  Millions
Iteos Therapeutics Inc   13.82 $ 599.027  Millions$ 43.349  Millions
Caribou Biosciences Inc   13.78 $ 338.488  Millions$ 24.572  Millions
Vor Biopharma Inc   13.75 $ 160.098  Millions$ 11.645  Millions
Aura Biosciences Inc   13.68 $ 149.076  Millions$ 10.894  Millions
Vigil Neuroscience Inc   13.18 $ 133.643  Millions$ 10.142  Millions
Anavex Life Sciences Corp   13.00 $ 151.024  Millions$ 11.617  Millions
Replimune Group Inc   12.47 $ 496.761  Millions$ 39.832  Millions
Elevation Oncology inc   12.46 $ 94.797  Millions$ 7.607  Millions
Allogene Therapeutics inc   12.37 $ 465.505  Millions$ 37.636  Millions
Ambrx Biopharma Inc   12.33 $ 225.262  Millions$ 18.268  Millions
Scholar Rock Holding Corp  11.19 $ 218.635  Millions$ 19.530  Millions
Kymera Therapeutics Inc   11.11 $ 357.825  Millions$ 32.219  Millions

Date modified: 2023-11-12T03:45:33+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com